First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations

被引：0
|
作者：
Tomohito Kuwako
Hisao Imai
Tomomi Masuda
Yosuke Miura
Kaori Seki
Reiko Yoshino
Kyoichi Kaira
Mitsuyoshi Utsugi
Kimihiro Shimizu
Noriaki Sunaga
Yoshio Tomizawa
Shinichi Ishihara
Takao Ishizuka
Akira Mogi
Takeshi Hisada
Koichi Minato
Atsushi Takise
Ryusei Saito
Masanobu Yamada
机构：
[1] Gunma University Graduate School of Medicine,Department of Medicine and Molecular Science
[2] Gunma Prefectural Cancer Center,Division of Respiratory Medicine
[3] National Hospital Organization Nishigunma Hospital,Division of Respiratory Medicine
[4] Gunma University Graduate School of Medicine,Department of Oncology Clinical Development
[5] Kiryu Kosei General Hospital,Division of Internal Medicine
[6] Gunma University Graduate School of Medicine,Department of Thoracic Visceral Organ Surgery
[7] Isesaki Municipal Hospital,Division of Internal Medicine
[8] Public Tomioka General Hospital,Division of Internal Medicine
[9] Gunma University Graduate School of Medicine,Department of General Surgical Science
[10] Maebashi Red Cross Hospital,Division of Respiratory Medicine
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 76卷
关键词：
Non-small cell lung cancer; Advanced non-small cell lung cancer; First-line chemotherapy; mutations; Gefitinib; Elderly patients;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：761 / 769
页数：8
相关论文
共 50 条
  • [1] First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations
    Kuwako, Tomohito
    Imai, Hisao
    Masuda, Tomomi
    Miura, Yosuke
    Seki, Kaori
    Yoshino, Reiko
    Kaira, Kyoichi
    Utsugi, Mitsuyoshi
    Shimizu, Kimihiro
    Sunaga, Noriaki
    Tomizawa, Yoshio
    Ishihara, Shinichi
    Ishizuka, Takao
    Mogi, Akira
    Hisada, Takeshi
    Minato, Koichi
    Takise, Atsushi
    Saito, Ryusei
    Yamada, Masanobu
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 761 - 769
  • [2] First-line gefitinib for elderly patients harboring EGFR mutations
    Asami, K.
    Koizumi, T.
    Amejima, S.
    Morikawa, A.
    Morozumi, N.
    Hirai, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
    Sequist, Lecia V.
    Martins, Renato G.
    Spigel, David
    Grunberg, Steven M.
    Spira, Alexander
    Jaenne, Pasi A.
    Joshi, Victoria A.
    McCollum, David
    Evans, Tracey L.
    Muzikansky, Alona
    Kuhlmann, Georgiana L.
    Han, Moon
    Goldberg, Jonathan S.
    Settleman, Jeffrey
    Iafrate, A. John
    Engelman, Jeffrey A.
    Haber, Daniel A.
    Johnson, Bruce E.
    Lynch, Thomas J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) : 2442 - 2449
  • [4] Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation
    An, Chaolun
    Zhang, Jiajun
    Chu, Hongjun
    Gu, Chunyan
    Xiao, Feng
    Zhu, Fengwei
    Lu, Rujian
    Shi, Hai
    Zhang, Hongfei
    Yi, Xin
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 763 - 768
  • [5] Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
    T. Masuda
    H. Imai
    T. Kuwako
    Y. Miura
    R. Yoshino
    K. Kaira
    K. Shimizu
    N. Sunaga
    Y. Tomizawa
    S. Ishihara
    A. Mogi
    T. Hisada
    K. Minato
    A. Takise
    R. Saito
    M. Yamada
    [J]. Clinical and Translational Oncology, 2015, 17 : 702 - 709
  • [6] Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations
    Masuda, T.
    Imai, H.
    Kuwako, T.
    Miura, Y.
    Yoshino, R.
    Kaira, K.
    Shimizu, K.
    Sunaga, N.
    Tomizawa, Y.
    Ishihara, S.
    Mogi, A.
    Hisada, T.
    Minato, K.
    Takise, A.
    Saito, R.
    Yamada, M.
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (09): : 702 - 709
  • [7] First-line gefitinib for elderly patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations: A combined analysis of NEJ studies.
    Narumi, Sodai
    Inoue, Akira
    Morikawa, Naoto
    Minegishi, Yuji
    Maemondo, Makoto
    Okinaga, Shoji
    Kobayashi, Kunihiko
    Harada, Toshiyuki
    Hagiwara, Koichi
    Nukiwa, Toshihiro
    Gemma, Akihiko
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] COST-UTILITY ANALYSIS OF FIRST-LINE GEFITINIB, ERLOTINIB AND AFATINIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS
    Holleman, M. S.
    Zaim, R.
    Uyl-De Groot, C. A.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A740 - A741
  • [9] Mefatinib as first-line treatment of patients with advanced non-small cell lung cancer harboring rare EGFR mutations.
    Wang, Pingli
    Cao, Liming
    Tian, Panwen
    Ren, Shengxiang
    Miao, Liyun
    Zhou, Chengzhi
    Fan, Yun
    Li, Yuping
    Lv, Dongqing
    Zhao, Xin
    Yang, Mei
    Zhu, Chaonan
    Xu, June
    Song, Yong
    Wang, Kai
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
    Ji, Y.
    Wang, X.
    Lou, Z.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S979 - S979
12345